Within just six months of its launch, Eli Lilly's Mounjaro has shaken up India’s pharmaceutical landscape. The once-a-week injectable drug, prescribed for type 2 diabetes and weight management, has turned out to be India’s second-highest selling medicine in September, according to industry tracker PharmaTrac.

The drug, which contains the active ingredient tirzepatide, recorded sales of Rs 80 crore in September, overtaking the antacid brand Pan (at Rs 77 crore) and coming close behind GlaxoSmithKline's antibiotic Augmentin, which led with Rs 85 crore in sales.

What’s remarkable is the speed of Mounjaro’s ascent, a 42% jump from Rs 56 crore in August.

A GLOBAL BLOCKBUSTER LANDS IN INDIA

Mounjaro, developed by US-based pharma giant Eli Lilly, first made headlines globally as a revolutiona

See Full Page